Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

This study analyzed approximately 950 men with low- or intermediate-risk disease. Patients were monitored using physical examinations, biopsies, and blood tests and were analyzed for the impact on overall survival, cost-specific survival, time to treatment, and PSA control.

In this study, the risk of dying from prostate cancer increased significantly when active surveillance was used in men with intermediate-risk disease compared with their low-risk counterparts.

View more from the 2015 GU Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer